Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

836 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.
Winston A, Stöhr W, Antinori A, Amieva H, Perré P, De Wit S, Reynes J, Gompels M, dʼArminio Monforte A, Gatell JM, Grarup J, Pozniak A, Babiker A, Raffi F, Richert L; NEAT 001ANRS 143 Study Group. Winston A, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):185-192. doi: 10.1097/QAI.0000000000001189. J Acquir Immune Defic Syndr. 2017. PMID: 27749603 Clinical Trial.
Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.
Plana M, Martínez C, García F, Maleno MJ, Barceló JJ, García A, Lejeune M, Vidal C, Cruceta A, Miró JM, Pumarola T, Gallart T, Gatell JM. Plana M, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):429-34. doi: 10.1097/00126334-200204150-00001. J Acquir Immune Defic Syndr. 2002. PMID: 11981357 Clinical Trial.
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Pulido F, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50. doi: 10.1097/00126334-200404010-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15097150
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3.
Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Plana M, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):791-9. doi: 10.1097/00126334-200407010-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15213562
Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study.
García F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, Vidal E, Millán O, López A, Martorell J, Fumero E, Miró JM, Alcamí J, Pumarola T, Gallart T, Gatell JM. García F, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):823-30. doi: 10.1097/00126334-200407010-00009. J Acquir Immune Defic Syndr. 2004. PMID: 15213566 Clinical Trial.
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Squires K, et al. Among authors: gatell jm. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9. doi: 10.1097/00126334-200408150-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15247553 Clinical Trial.
Long-term clinical follow-up, without antiretroviral therapy, of patients with chronic HIV-1 infection with good virological response to structured treatment interruption.
Florence E, García F, Plana M, Fumero E, Castro P, Lopez A, Cruceta A, Gil C, Arnedo M, Miró JM, Pumarola T, Gallart T, Gatell JM. Florence E, et al. Among authors: gatell jm. Clin Infect Dis. 2004 Aug 15;39(4):569-74. doi: 10.1086/422720. Epub 2004 Aug 3. Clin Infect Dis. 2004. PMID: 15356824
836 results